Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder

Wu, Ching-Kuan; Tseng, Ping‐Tao; Chen, Yen‐Wen; Tu, Kun-Yu; Lin, Pao‐Yen

doi:10.1097/md.0000000000004563

Cited by 29 publications

(29 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is especially suggestive that work from the Pritzker Neuropsychiatric Disorder Research Consortium allowed the important discovery that FGF, originally implicated in neural development, plays a crucial role in neurogenesis and in neuroplasticity in adulthood, suggesting a neuromodulatory function in anxiety-like and depression-like behaviors [47,48], providing support for our findings. In addition, altered levels of FGF family members were revealed in MDD patients, both in blood and in brain [49]. Altered levels of IGF-1, a neurotrophic, neurogenetic and neuroprotective factor, were repeatedly reported in MDD patients, although with conflicting results in the direction of change [46].…”

Section: Discussionmentioning

confidence: 99%

Cross-species evidence from human and rat brain transcriptome for growth factor signaling pathway dysregulation in major depression

Carboni

Marchetti

Lauria

et al. 2018

Neuropsychopharmacol

View full text Add to dashboard Cite

An enhanced understanding of the pathophysiology of depression would facilitate the discovery of new efficacious medications. To this end, we examined hippocampal transcriptional changes in rat models of disease and in humans to identify common disease signatures by using a new algorithm for signature-based clustering of expression profiles. The tool identified a transcriptomic signature comprising 70 probesets able to discriminate depression models from controls in both Flinders Sensitive Line and Learned Helplessness animals. To identify disease-relevant pathways, we constructed an expanded protein network based on signature gene products and performed functional annotation analysis. We applied the same workflow to transcriptomic profiles of depressed patients. Remarkably, a 171-probesets transcriptional signature which discriminated depressed from healthy subjects was identified. Rat and human signatures shared the SCARA5 gene, while the respective networks derived from protein-based significant interactions with signature genes contained 25 overlapping genes. The comparison between the most enriched pathways in the rat and human signature networks identified a highly significant overlap (p-value: 3.85 × 10) of 67 terms including ErbB, neurotrophin, FGF, IGF, and VEGF signaling, immune responses and insulin and leptin signaling. In conclusion, this study allowed the identification of a hippocampal transcriptional signature of resilient or susceptible responses in rat MDD models which overlapped with gene expression alterations observed in depressed patients. These findings are consistent with a loss of hippocampal neural plasticity mediated by altered levels of growth factors and increased inflammatory responses causing metabolic impairments as crucial factors in the pathophysiology of MDD.

show abstract

Section: Discussionmentioning

confidence: 99%

Cross-species evidence from human and rat brain transcriptome for growth factor signaling pathway dysregulation in major depression

Carboni

Marchetti

Lauria

et al. 2018

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Insulin-like growth factor-1 is an additional factor with neurogenic functions that may be increased in depression, reflecting an imbalance in neurotrophic processes 82,83. Basic fibroblast growth factor (or FGF-2) is a member of the fibroblast growth factor family and appears higher in depressed than control groups 84. However, reports are not consistent; one found that this protein was lower in MDD than healthy controls, but reduced further alongside antidepressant treatment 85…”

Section: Introductionmentioning

confidence: 99%

Biomarkers for depression: recent insights, current challenges and future prospects

Strawbridge¹,

Young²,

Cleare³

2017

NDT

306

156

View full text Add to dashboard Cite

A plethora of research has implicated hundreds of putative biomarkers for depression, but has not yet fully elucidated their roles in depressive illness or established what is abnormal in which patients and how biologic information can be used to enhance diagnosis, treatment and prognosis. This lack of progress is partially due to the nature and heterogeneity of depression, in conjunction with methodological heterogeneity within the research literature and the large array of biomarkers with potential, the expression of which often varies according to many factors. We review the available literature, which indicates that markers involved in inflammatory, neurotrophic and metabolic processes, as well as neurotransmitter and neuroendocrine system components, represent highly promising candidates. These may be measured through genetic and epigenetic, transcriptomic and proteomic, metabolomic and neuroimaging assessments. The use of novel approaches and systematic research programs is now required to determine whether, and which, biomarkers can be used to predict response to treatment, stratify patients to specific treatments and develop targets for new interventions. We conclude that there is much promise for reducing the burden of depression through further developing and expanding these research avenues.

show abstract

“…Some studies have focused on the role of neuronal regeneration in the pathogenesis and treatment for depression. According to the neurotrophic hypothesis of depression, brain derived neurotrophic factor (BDNF), tumor necrosis factor-α (TNF-α) ( 9 ), vascular endothelial growth factor (VEGF) ( 10 ) or fibroblast growth factor 2 (FGF-2) ( 11 ) may participate in the progression of depression.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-27a participates in the pathological process of depression in rats by regulating VEGFA

Cui¹,

Gong²,

Cao³

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

The present study aimed to determine the expression of vascular endothelial growth factor A (VEGFA) and microRNA (miRNA/miR)-27a in hippocampal tissues, and serum from a depression model of rats. In addition, the present study aimed to understand the mechanism of regulation of miR-27a in depression. A total of 40 male rats were selected, and divided into the control and depression model groups. The rats in the model group were subjected to 14 types of stimulations to model depression. By determining the body weight, syrup consumption rate and open field test score, the extent of depression in the rats was evaluated. Quantitative-polymerase chain reaction was used to determine the expression of VEGFA mRNA and miR-27a in hippocampal tissues, and serum. ELISA was used to measure the content of VEGFA protein in serum, while western blotting was employed to determine the expression of VEGFA protein in hippocampal tissues. A dual luciferase assay was carried out to identify the interactions between VEGFA mRNA and miR-27a. The rats in the depression model group showed depression symptoms and the depression model was successfully constructed. Rats with depression had lower VEGFA mRNA and protein expression in the hippocampus, and peripheral blood compared with the control group. Rats in the depression model group had reduced levels of miR-27a in the hippocampus and peripheral blood, which may be associated with the levels of VEGFA. miR-27a was able to bind with the 3′-untranslated region of VEGFA mRNA to regulate its expression. The present study demonstrated that miR-27a expression in hippocampal tissues and blood from rats with depression is upregulated, while the expression of VEGFA mRNA and protein is downregulated. miR-27a may participate in the pathological process of depression in rats by regulating VEGFA.

show abstract

Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder

Abstract: Supplemental Digital Content is available in the text

Cited by 29 publications

References 45 publications

Cross-species evidence from human and rat brain transcriptome for growth factor signaling pathway dysregulation in major depression

Cross-species evidence from human and rat brain transcriptome for growth factor signaling pathway dysregulation in major depression

Biomarkers for depression: recent insights, current challenges and future prospects

MicroRNA-27a participates in the pathological process of depression in rats by regulating VEGFA

Contact Info

Product

Resources

About